Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...
Repeated weight loss and gain — known as yo-yo dieting — has been linked to kidney disease in type 1 diabetes patients. A recent study found that individuals with greater weight fluctuations were more ...